Merck's Meteoric Rise: Is the Pharma Giant Still a Bargain After Years of Stellar Gains?
Merck & Co. shares have delivered impressive multi-year returns, climbing over 80% in the past five years. Yet, a deep dive into its valuation metrics suggests the market may still be underestimating the pharmaceutical leader's intrinsic value, presenting a potential opportunity for investors.